ARQTArcutis Biotherapeutics Inc
ARQT
Arcutis Biotherapeutics Inc2,457
Mkt Cap
$3.05BVolume
35,041.0052W High
$31.7752W Low
$12.42PE Ratio
-175.70ARQT Fundamentals
Price
$24.24Prev Close
$24.58Open
$24.6050D MA
$24.61Beta
1.40Avg. Volume
1.41MEPS (Annual)
-$0.1269P/B
16.00Rev/Employee
$1.06M$3,587.81
Phocas Financial Corp. Trims Stake in Arcutis Biotherapeutics, Inc. $ARQT
Phocas Financial Corp. reduced its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 39.3% during the fourth quarter, according to the company in its most recent 13F filing with...
MarketBeat·4h ago
Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow Positive
Arcutis Biotherapeutics (NASDAQ:ARQT) executives told investors at Needham's 25th Annual Healthcare Conference that the company is focused on expanding the ZORYVE topical franchise across inflammatory skin conditions while investing in pipeline opportunities, following what management described as a...
MarketBeat·1d ago
Tudor Investment Corp ET AL Makes New Investment in Arcutis Biotherapeutics, Inc. $ARQT
Tudor Investment Corp ET AL purchased a new position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 69,980 shares of the company's stock, valued at approxi...
MarketBeat·2d ago
AMI Asset Management Corp Sells 46,829 Shares of Arcutis Biotherapeutics, Inc. $ARQT
AMI Asset Management Corp lessened its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 48.7% during the fourth quarter, according to its most recent filing with the Securities...
MarketBeat·2d ago
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Average Recommendation of "Moderate Buy" by Analysts
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eight brokerages that are covering the stock, MarketBeat reports. One...
MarketBeat·5d ago
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Acquired Rep. Gilbert Ray Cisneros, Jr.
Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Arcutis Biotherapeutics stock on March 3rd. The...
MarketBeat·7d ago
Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know
Key PointsA director of Arcutis Biotherapeutics reported selling 10,000 shares for a total transaction value of $239,000 on April 1, 2026...
Nasdaq News: Markets·8d ago
Arcutis Biotherapeutics, Inc. $ARQT Shares Sold by JPMorgan Chase & Co.
JPMorgan Chase & Co. decreased its holdings in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 81.6% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 100,794 shares of the company's stock after selling 447,995 shares during the per...
MarketBeat·8d ago
Aberdeen Group plc Sells 88,637 Shares of Arcutis Biotherapeutics, Inc. $ARQT
Aberdeen Group plc lowered its holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 13.1% in the fourth quarter, according to its most recent 13F filing with the Securities...
MarketBeat·9d ago
Perpetual Ltd Sells 1,113,976 Shares of Arcutis Biotherapeutics, Inc. $ARQT
Perpetual Ltd lowered its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 55.0% during the 4th quarter, according to its most recent Form 13F filing with the...
MarketBeat·12d ago
<
1
2
...
>